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steatohepatitis paved with triglyceride
or cholesterol?
Accumulation of hepatic lipids has been thought to trigger the inflammation, apoptosis, and fibrosis that characterize pro-
gression of hepatic steatosis to steatohepatitis and cirrhosis. In this issue of Cell Metabolism, Marı´ et al. (2006) provide
evidence for excessivemitochondrial free cholesterol as a cause of the progession of steatosis tomore severe liver disease.Nonalcoholic fatty liver disease (NAFLD)
ranges in severity from steatosis to stea-
tohepatitis to the above plus fibrosis
leading to cirrhosis. Recent observational
studies indicate a prevalence as high as
25% in the United States (Farrell and Lar-
ter, 2006; Browning and Horton, 2004),
where NAFLD may be a leading cause
of cryptogenic cirrhosis. Although most
individuals with NAFLD seem to either re-
main stable or improve over time, little is
known about the progression of this dis-
order to steatohepatitis and cirrhosis.
Much of the increased prevalence of
NAFLD is driven by obesity. However,
high rates of NAFLD in relatively normal
weight people (by Western standards)
from the Indian subcontinent and South-
east Asia suggest that, even in the ab-
sence of obesity, insulin resistance leads
to hepatic fat accumulation. Indeed, pa-
tients with total lipodystrophy, who have
no adipose tissue, have severe insulin re-
sistance with marked hepatic steatosis.
Studies of the molecular basis of NAFLD
have largely focused on triglyceride (TG),
the major lipid stored in hepatocytes. Al-
though much is known about the regula-
tion of hepatic TG synthesis, secretion,
and storage, much less is known about
the roleofTGand/or its precursors instim-
ulating the inflammatory changes needed
for the progression of steatosis to steato-
hepatitis. In this issue of Cell Metabolism,
Marı´ et al. (2006) move the spotlight to
cholesterol, and in particular mitochon-
drial freecholesterol, asacentralmolecule
in the pathogenesis of steatohepatitis.
Hepatic TG levels are determined by
the availability of fatty acids (FA) from
the circulation, de novo lipogenesis of
FA from glucose, oxidation of FA, and
the secretion of TG on very low-density li-
poproteins (VLDL) (Figure 1A) (Goldberg
and Ginsberg, 2006). Each of these
processes may be altered by insulin
resistance in ways that predispose to
steatosis. Thus, insulin resistance leads
to increased lipolysis of adipocyte TGCELL METABOLISM : SEPTEMBER 2006andmore FA flux to the liver (Yu andGins-
berg, 2005). Insulin resistance may be
associated with reduced lipoprotein li-
pase-mediated lipolysis of plasma chylo-
micron or VLDL TG, leading to hepatic
uptake of remnant lipoproteins carrying
more TG than normal. De novo lipogene-
sis is increased in insulin resistance; in-
sulin-mediated stimulation of SREBP-1c
is a key contributor, although glucose-
mediatedstimulationofChREBPcanalso
play a significant role (Browning and
Horton, 2004). Aberrant expression of
PPARg2 in insulin resistance livers can
also stimulatedenovo lipogenesis (Gavri-
lova et al. 2003). Oxidation of hepatic FA
is regulated at several points, but is likely
to be limited in the face of adequate he-
patic glycogen and increased lipogene-
sis with elevated levels of malonyl-CoA.
Finally, insulin can target apoB for post-
translational degradation; the balance
between systemic hyperinsulinemia and
hepatic insulin resistance will determine
how much apoB will be available to carry
TG out of the hepatocyte (Figure 1B).
It has been shown that increased he-
patic TG stimulates increased VLDL TG
secretion by targeting apoB away from
degradation and toward secretion and/
or by increasing the amount of TG on
each VLDL (Fisher and Ginsberg, 2002).
However, recent studies suggest greater
complexity. For example, stimulation of
hepatic lipogenesis by an LXR agonist
results in increased TG secretion but
has no effect on apoB secretion. In vivo
overexpression of mtGPAT, an enzyme
that synthesizes diglycerides, increases
both hepatic TG content and secretion
(Linden et al., 2006), but overexpression
of either DGAT1 or DGAT2, enzymes
that synthesize TG and increase hepatic
TG, has had inconsistent effects on TG
secretion (Millar et al., 2006). On the other
hand, we demonstrated that increased
delivery of FA to the liver can increase
apoB secretion without increasing TG
secretion (Zhang et al., 2004). Together,these results indicate compartmentaliza-
tion of hepatic TG into pools with tight or
loose connections to TG secretion or dif-
ferential effects of FA and TG on apoB
and TG secretion. To further complicate
matters, levels of lipid droplet proteins
such as ADRP and perilipin, activities of
hepatic lipases such as TGH, ATGL,
and HSL, and the activity of MTP (which
transfers endoplasmic reticulum TG and
cholesterol onto apoB) may all confound
the relationship between hepatic TG ac-
cumulation and the assembly and secre-
tion of VLDL.
How steatosis progresses to steatohe-
patitis is under intense investigation. In-
flammation, together with evidence of
apoptosis and necrosis of hepatocytes,
differentiates steatohepatitis from stea-
tosis. Most investigators accept a ‘‘two-
hit’’ hypothesis; steatosis appears to be
the required background abnormality
upon which inflammation, cellular dys-
function, and cell death can occur. In-
creased FA oxidation and ROS formation
could lead to a state of oxidative stress,
with sequelae that include lipid peroxida-
tion, membrane damage, and mitochon-
drial dysfunction, the latter leading to
more ROS formation. However, the evi-
dence that there is increased FA oxida-
tion in steatotic livers is limited. In their
paper, Marı´ et al. (2006) present evidence
supporting an alternative lipid-based
mechanism for the progression of steato-
sis to steatohepatitis (Figure 1C). These
authors propose and provide experi-
mental evidence for a specific role for
accumulation of free cholesterol in mito-
chondria leading to mitochondrial gluta-
thione depletion and sensitivity to TNFa
and FAS mediated pathways of apopto-
sis. Using two diets, one that was choline
deficient and one with 2% cholesterol
plus sodium cholate, they specifically in-
creased either hepatic TG or cholesterol,
respectively. They demonstrated that
TNFa treatment caused apoptosis, ne-
crosis, and ROS formation only in livers179
P R E V I E W SFigure 1. Hepatic lipid metabolism in steatosis and steatohepatitis
A) Hepatic TG homeostasis is maintained through a balance of the delivery of albumin bound fatty acids (FA)
or triglyceride (TG) FA in remnant lipoproteins, de novo synthesis of FA from glucose via lipogenesis, oxidation
of FA, and the assembly and secretion of TG and apolipoprotein B (apoB) as very low-density lipoproteins
(VLDL).
B) Insulin resistance and obesity can result in steatosis because of increased delivery of FA and TGFA,
increased lipogenesis driven by SREBP-1c, ChREPB, and possibly aberrant expression of PPARg, and
decreased fatty acid oxidation secondary to increased lipogenesis and levels of malonyl CoA. Plasma hyper-
insulinemia with modest hepatic insulin resistance (IR) could result in increased insulin-mediated degradation
of apoB and more steatosis. Blue arrows indicate pathways or processes that will stimulate hepatic TG
production and/or secretion; red arrows indicate inhibition of those pathways or processes.
C) The progression of hepatic steatosis to steatohepatitis requires insults in addition to steatosis: these include
oxidative stress, production of reactive oxygen species (ROS), lipid peroxidation, the actions of cytokines such
as TNFa, and according to the work of Marı´ et al. (2006), increased mitochondrial free cholesterol (FC) with
loss of glutathione and increased sensitivity to TNFa.180with increased cholesterol (with or with-
out increased TG) content. These inves-
tigators further showed that the free
cholesterol content of mitochondria was
increased, at least transiently, on the
high-cholesterol/cholate diet and that
this was associated with altered mem-
brane fluidity and reduced glutathione
content. Additional experiments, inwhich
mitochondrial glutathione was depleted
with a smallmolecule, reiterated the over-
all effects of increased mitochondrial
cholesterol. Finally, treatment with the
HMG-CoA reductase inhibitor, atorvasta-
tin, reduced mitochondrial free choles-
terol and increased mitochondrial gluta-
thione levels in livers from rats fed the
high-cholesterol/cholate diet. Signs of
steatohepatitis were ameliorated as well.
So, is altered hepatic cholesterol me-
tabolism,andspecifically increasedmito-
chondrial cholesterol concentration, the
missing lipid-link between steatosis and
steatohepatitis? The data of Marı´ et al.
(2006) are certainly intriguing and sug-
gestive. It would help to knowmore about
the effects of the diet with high choles-
terol but without cholate, as these two
dietary components have been shown
to induce different sets of genes impor-
tant for hepatic inflammation and fibrosis
(Vergness et al., 2003). It would also be
helpful if diets lower in cholesterol had
beenused: a 2%cholesterol diet is equiv-
alent to an intake of more than 2000
mg/day of dietary cholesterol in man, in
whom the average dietary cholesterol in-
take is 300mg/day. Additionally, the tran-
sient nature of the rise in mitochondrial
free cholesterol, due to increased acyl-
CoA:cholesteryl acyltransferase (ACAT)
expression and activity in the high-cho-
lesterol-fed rats, points to the need to de-
termine if mitochondrial free cholesterol
levels differed between the cholesterol-
fed and the choline-deficient diet-fed
mice after 1 week. With those caveats
in mind, Marı´ et al. (2006) have clearly
opened the way for more careful exami-
nations of hepatic lipids; it is time to
move beyond TG and also investigate
the role of hepatic cholesterol in various
mousemodels of steatosis. If the present
data are supported by further studies,
new approaches to therapy could follow.
Present therapies targeted at increas-
ing insulin sensitivity, increasing FA oxi-
dation, or reducing TG synthesis are all
logical based on a large body of data
collected over the past two decades.
Hepatic cholesterol may become anCELL METABOLISM : SEPTEMBER 2006
P R E V I E W Sadjunctive or alternative target if these
new data are confirmed. Of course, pre-
vention of steatosis by proper nutrition
and exercise remains our primary goal.
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